Anti-SARS-CoV-2 neutralizing monoclonal antibodies: clinical pipeline

  • Marco Tuccori
    Unit of Adverse Drug Reactions Monitoring, University Hospital of Pisa, Pisa, Italy
  • Sara Ferraro
    Unit of Pharmacology and Pharmacovigilance, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy
  • Irma Convertino
    Unit of Pharmacology and Pharmacovigilance, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy
  • Emiliano Cappello
    Unit of Pharmacology and Pharmacovigilance, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy
  • Giulia Valdiserra
    Unit of Pharmacology and Pharmacovigilance, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy
  • Corrado Blandizzi
    Unit of Adverse Drug Reactions Monitoring, University Hospital of Pisa, Pisa, Italy
  • Fabrizio Maggi
    Division of Microbiology, Varese University Hospital, Varese, Italy
  • Daniele Focosi
    Pisa University Hospital, Pisa, Italy

収録刊行物

  • mAbs

    mAbs 12 (1), 1854149-, 2020-01-01

    Informa UK Limited

被引用文献 (5)*注記

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ